

What is claimed is:

1. An aqueous solution that comprises recombinant granulocyte macrophage colony-stimulating factor, wherein said solution further comprises from 0.1 mM to 50 mM EDTA.
2. The aqueous solution of claim 1, wherein the concentration of EDTA is 0.1 to 5 mM.
3. The aqueous solution of claim 1, wherein the recombinant granulocyte macrophage colony-stimulating factor is sargramostim.
4. The aqueous solution of claim 3, wherein the EDTA concentration is 5 mM, and wherein the solution has a pH of 7.4 and further comprises 10 mM TRIS-HCL, 40 mg/ml mannitol, 10 mg/ml sucrose.
5. A process for preparing a stablized aqueous solution of granulocyte macrophage colony-stimulating factor, which comprises adding EDTA at a concentration of 0.1 to 50 mM to a solution comprising 500 µg/ml granulocyte macrophage colony-stimulating factor, 10 mM TRIS-HCL, 40 mg/ml mannitol and 10 mg/ml sucrose.
6. The process of claim 5, wherein the EDTA is added at a concentration of 5 mM.
7. The process of claim 5, wherein the recombinant granulocyte macrophage colony-stimulating factor is sargramostim.
8. The process of claim 7, further comprising the step of lyophilizing the aqueous solution.
9. A therapeutic method comprising administering to a patient in need thereof an aqueous solution of granulocyte macrophage colony-stimulating factor according to claim 3.